Perioperative Chemotherapy in Resectable Neuroendocrine Carcinomas of the Digestive Tract

#2189

Introduction: Neuroendocrine carcinomas (NEC), of the digestive tract are rare and aggressive tumours. In localised disease, the treatment is surgery, followed by administration of adjuvant chemotherapy combining etoposide and platinum salts, justified by the high risk of secondary metastasis. No clinical study has proven the benefit of chemotherapy, and recommendations are based on expert consensus.

Aim(s): The aim of our study was to evaluate the effect of chemotherapy in this indication.

Materials and methods: We performed a retrospective observational multicentre French study collecting patients’ data from medical files. We evaluated the overall survival (OS) and progression free survival (PFS) for our population. We studied prognostic factors for survival and chemotherapy toxicity.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Pellat A, Walter T, Hautefeuille V, Hentic O, Augustin J,

Keywords: neuroendocrine, carcinoma, chemotherapy, Ki-67,